ReviewThyroid research2025
Prognostic impact of RAS mutation on papillary thyroid carcinoma: a systematic review and meta-analysis.
Review in Thyroid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The critical role of ferroptosis in thyroid cancer development and potential therapeutic implications.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPapillary thyroid carcinoma (PTC) is the most common form of thyroid malignancy, and activating mutations in the RAS gene family have been implicated in its pathogenesis and clinical behavior. This study aimed to evaluate the role of RAS mutations in clinical outcomes of patients with PTC.
methodsWe conducted a comprehensive literature search of PubMed, Scopus, and WOS. Eligible studies included data on RAS mutation prevalence and at least one of the predefined endpoints. Hazard ratios (HR) for recurrence-free survival (RFS), odds ratios (OR) for mortality, distant metastasis, and tumor recurrence, and mean differences (MD) for tumor size were used as effect sizes.
resultsA total of 22 studies, involving 4727 patients, were included in this analysis. The pooled prevalence of RAS mutations was 20% (95% CI: 14%-28%). Presence of RAS mutation was associated with significantly higher odds of distant metastasis (OR = 3.12, 95% CI: 1.48-6.59, p < 0.01), while no significant associations were found with RFS (HR = 1.05, 95% CI: 0.52-2.13, p = 0.88), overall mortality (OR = 2.01, 95% CI: 0.60-6.70, p = 0.21), tumor recurrence (OR = 0.35; 95% CI: 0.08-1.61, p = 0.13). Moreover, our findings revealed no significant differences in tumor size between RAS-positive and RAS-negative cases (MD = 0.01, 95% CI: -0.73-0.72, p = 0.96).
conclusionsRAS mutations are present in 20% of PTC cases and are associated with increased risk of distant metastasis. However, these mutations were not significantly associated with other clinical outcomes. These findings support the integration of RAS mutation testing into postoperative risk stratification to identify patients who may benefit from more intensive surveillance and personalized therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.